Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
MOTS-c is mitochondria-derived, working at the cellular energy level rather than signaling GH or repairing tissue
Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo [4]
Its been studied extensively in animal models for its regenerative and protective effects, showing promise for the nervous system, gut, and connective tissue
In some embodiments, the lipid-based drug delivery formulation is a phospholipid-based formulation (e.g., hydrogenated or nonhydrogenated phospholipids, lecithins, phosphatidyl cholines (C8-C18), phosphatidylethanolamines (C8-C18), phosphatidylglycerols (C8-C18)) wherein the phospholipid is phospholipon 90H (1,2-dia-cyl-SN-glycero-3-phosphatidyl choline), egg phospholipids P123, Lipoid E80
The standard reconstitution fluid for peptides, allowing multi-dose vial use over weeks
US$ 27.95
US$ 25.63
US$ 23.60
US$ 25.78